Cargando…

Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer

Cyclin-dependent kinase (CDK) 4/6 inhibitors have shown great results in numerous clinical trials and have improved the clinical outcome for patients with hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer significantly. To date, three CDK4/6 inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thill, Marc, Schmidt, Marcus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122233/ https://www.ncbi.nlm.nih.gov/pubmed/30202447 http://dx.doi.org/10.1177/1758835918793326

Ejemplares similares

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences
por: Johnston, Stephen, et al.
Publicado: (2023)

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2021)

Adverse Cardiovascular Events Associated With Cyclin‐Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer
por: Fradley, Michael G., et al.
Publicado: (2023)

Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study
por: Yıldırım, Hasan Çağrı, et al.
Publicado: (2022)

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
por: Finn, Richard S., et al.
Publicado: (2016)

Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells
por: Ogata, Ryohei, et al.
Publicado: (2020)

Predicting clinical benefit from continuation of cyclin dependent kinase (CDK) 4/6 inhibitors beyond progression
por: Foldi, Julia, et al.
Publicado: (2023)

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
por: Kang, Jian, et al.
Publicado: (2014)

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
por: De Angelis, Claudia, et al.
Publicado: (2020)

Are all cyclin-dependent kinases 4/6 inhibitors created equal?
por: Marra, Antonio, et al.
Publicado: (2019)

The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer
por: Tanaka, Tomohito, et al.
Publicado: (2017)

The Role of Cyclin-Dependent Kinases (CDK) 4/6 in the Ovarian Tissue and the Possible Effects of Their Exogenous Inhibition
por: Scavone, Graziana, et al.
Publicado: (2023)

Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
por: Raschi, Emanuel, et al.
Publicado: (2020)

The Open Issues Regarding Cyclin-Dependent Kinase 4/6 Inhibitors in the Management of Advanced Breast Cancer
por: Rossi, Lorenzo
Publicado: (2018)

Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer
por: Husinka, Lakyn, et al.
Publicado: (2020)

Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment
por: Susanti, Ni Made Pitri, et al.
Publicado: (2021)

Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms
por: Wang, Bin, et al.
Publicado: (2021)

Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
por: Hanna, Paul E., et al.
Publicado: (2023)

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines
por: Coxon, Christopher R., et al.
Publicado: (2016)

Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation
por: Bashour, Sami I., et al.
Publicado: (2017)

The Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Relapsed Ectopic Male Breast Cancer
por: Baek, Dong Won, et al.
Publicado: (2020)

Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies
por: Niu, Ying, et al.
Publicado: (2019)

Latest Overview of the Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: The Past, the Present and the Future
por: Chen, Xiu, et al.
Publicado: (2019)

Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Quantum Leap in the Treatment of Advanced Breast Cancers
por: Reddy, Sanjana, et al.
Publicado: (2022)

Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
por: Tavakolian, Shaian, et al.
Publicado: (2020)

Comparison of deregulated expression of cyclin D1 and cyclin E with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squamous cell carcinoma
por: Matsumoto, M, et al.
Publicado: (1999)

Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper
por: Battisti, Nicolò Matteo Luca, et al.
Publicado: (2018)

Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study
por: Sollena, Pietro, et al.
Publicado: (2023)

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
por: Pack, Lindsey R., et al.
Publicado: (2021)

Deciphering the Immunomodulatory Role of Cyclin-Dependent Kinase 4/6 Inhibitors in the Tumor Microenvironment
por: Pandey, Pratibha, et al.
Publicado: (2023)

Cyclin-dependent kinase 4/6 inhibition in cancer therapy
por: Johnson, Neil, et al.
Publicado: (2012)

Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review
por: Sharaf, Baha', et al.
Publicado: (2022)

CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
por: Preusser, Matthias, et al.
Publicado: (2018)

Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
por: Bisi, John E., et al.
Publicado: (2017)

Lineage specific composition of cyclin D–CDK4/CDK6–p27 complexes reveals distinct functions of CDK4, CDK6 and individual D‐type cyclins in differentiating cells of embryonic origin
por: Bryja, V., et al.
Publicado: (2008)

Efficacy and Safety of Cyclin-Dependent Kinases 4 and 6 Inhibitors in HR+/HER2− Advanced Breast Cancer
por: Xie, Ning, et al.
Publicado: (2020)

Safety of cyclin-dependent kinase4/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer
por: Kim, Kristine N., et al.
Publicado: (2021)

Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review
por: Zhao, Melody, et al.
Publicado: (2023)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
por: Yang, C, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ii27o6h223fafa2sqf8b6oo8rh